Swedbank AB Purchases 2,220 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Swedbank AB lifted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 44.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,195 shares of the medical instruments supplier’s stock after purchasing an additional 2,220 shares during the period. Swedbank AB’s holdings in West Pharmaceutical Services were worth $2,160,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fidelis Capital Partners LLC purchased a new position in West Pharmaceutical Services in the first quarter worth $27,000. Crewe Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 322.7% in the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 71 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in West Pharmaceutical Services during the first quarter valued at about $40,000. Northwest Investment Counselors LLC purchased a new stake in West Pharmaceutical Services during the first quarter worth about $40,000. Finally, ORG Partners LLC raised its position in West Pharmaceutical Services by 820.0% in the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock worth $55,000 after acquiring an additional 123 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the sale, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.53% of the stock is owned by corporate insiders.

West Pharmaceutical Services Stock Up 1.6 %

WST opened at $293.32 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The company’s 50-day moving average price is $299.96 and its two-hundred day moving average price is $325.39. The stock has a market cap of $21.37 billion, a price-to-earnings ratio of 38.70, a PEG ratio of 10.53 and a beta of 1.01. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. During the same quarter in the previous year, the company posted $2.11 EPS. West Pharmaceutical Services’s revenue for the quarter was down 6.9% on a year-over-year basis. As a group, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.